Synthesis of a C-Iminoribofuranoside Analog of the Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitor FK866

Gillig, AnnabelleMajjigapu, Somi ReddySordat, BernardVogel, Pierre2012-03-012012-03-012012-03-01201210.1002/hlca.201100415https://infoscience.epfl.ch/handle/20.500.14299/78276WOS:000299160000003FK866 (also named APO866 or WK175) is a potent NAMPT inhibitor being evaluated (Phase II) as a potential anticancer drug. The preparation of the C-iminoribofuranoside analog (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-{3-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]phenyl}prop-2-enamide ((-)-1) is reported.Ribofuranoside analogsC-imino-Fk866Nicotinamide phosphoribosyltransferaseInhibitorsNad Biosynthesis InhibitorPotent Antitumor-ActivityHuman Leukemia-CellsIn-VitroHematologic MalignanciesPyridine-NucleotidesColorectal-CancerChs 828VisfatinTargetSynthesis of a C-Iminoribofuranoside Analog of the Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitor FK866text::journal::journal article::research article